Mycophenolate mofetil (Cellcept) in pediatric renal transplantation

Area of Science:

• Nephrology
• Immunosuppression
• Pediatric Transplantation

Background:

• Mycophenolate mofetil (MMF) has been utilized in pediatric renal transplantation for nearly a decade.
• Standard immunosuppression with steroids and calcineurin inhibitors (CNI) in pediatric kidney recipients is linked to adverse effects like growth issues and hypertension.
• MMF has demonstrated potential in improving graft survival and renal function in pediatric kidney transplant patients.

Purpose of the Study:

• To evaluate the role and benefits of Mycophenolate mofetil (MMF) in pediatric renal transplantation.
• To assess the impact of MMF on graft survival, renal function, and the necessity of other immunosuppressants.
• To review the safety profile and efficacy of MMF-based immunosuppressive protocols in children.

Main Methods:

• Review of pediatric studies on Mycophenolate mofetil (MMF) in renal transplantation.
• Analysis of MMF's impact on graft survival and renal function when used with steroids and calcineurin inhibitors (CNI).
• Investigation into MMF's role in enabling the reduction of CNI and steroid dosages.

Main Results:

• MMF is associated with improved graft survival and renal function in pediatric kidney transplant recipients.
• MMF facilitates the reduction of calcineurin inhibitors (CNI) without increasing rejection rates, leading to better blood pressure and renal function.
• Steroid-sparing protocols, including those with CNI, show clinical benefits, and newer combinations aim to reduce both steroids and CNI.

Conclusions:

• Mycophenolate mofetil (MMF) is a crucial component of immunosuppressive regimens in pediatric renal transplantation.
• MMF contributes to improved patient outcomes and allows for the minimization of toxic immunosuppressants.
• Ongoing research supports the use of MMF and novel combinations for optimized immunosuppression in pediatric kidney transplant patients.